Isabelle Cano

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

P. Cony-Makhoul, S. de Botton, P. Rousselot, 2018, Leukemia & lymphoma.